A phase I study of combination therapy with immunotoxins IgG-HD37- deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma

Richard A. Messmann, Ellen S. Vitetta, Donna Headlee, Adrian M. Senderowicz, William D. Figg, John Schindler, Dennis F. Michiel, Steven Creekmore, Seth M. Steinberg, David Kohler, Elaine S. Jaffe, Maryalice Stetler-Stevenson, Huachun Chen, Victor Ghetie, Edward A. Sausville

Research output: Contribution to journalArticlepeer-review

114 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I study of combination therapy with immunotoxins IgG-HD37- deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences